Pharmaceutical formulation of apomorphine for buccal administration

a technology of apomorphine and apomorphine, which is applied in the direction of heterocyclic compound active ingredients, biocide, drug compositions, etc., can solve the problems of limited application of apomorphine to control “on-off” fluctuations, transient nasal blockage and burning sensation, and promote sexual function , the effect of enhancing libido
US20090023766A1Inactive Publication Date: 2009-01-22AMARIN PHARMA IRELAND
5 Cites 36 Cited by

Patent Information

Authority / Receiving Office
US · United States
Current Assignee / Owner
AMARIN PHARMA IRELAND
Publication Date
2009-01-22
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH modifying agent; the components being presented such that they can be combined at the point of use into a formulation which is adjusted to a pH ranging from mildly acidic to alkaline and which is suitable for buccal administration. The formulation is useful in treating Parkinson's disease and in promoting sexual function.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] The present invention relates to pharmaceutical formulations of apomorphine, a drug used in the management of Parkinson's disease and in the treatment of sexual dysfunction. More specifically the invention relates to pharmaceutical formulations of apomorphine which are for buccal administration.BACKGROUND OF THE INVENTION

[0002] Parkinson's disease is a chronic, progressive neurological disorder affecting approximately 20 in every 100,000 people. The disease is typically characterised by resting tremor, muscle rigidity, bradykinesia and postural instability. Although the exact pathological course of Parkinson's disease is unknown, the dopaminergic neurones in the substantia nigra are progressively destroyed which leads to a net decrease in the amount of dopamine in the basal ganglia. Dopamine replacement with levodopa is the current primary therapy for Parkinson's disease.

[0003] After a three to five year period of control, 25% of Parkinson's disease suffere...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More